Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) – is there still a role after comparison with palonosetron?

References

• Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482–2494.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 2000;18:163–173.
   PubMed Web of Science ®Google Scholar
• Saito M, Aogi A, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10:115–124.
   PubMed Web of Science ®Google Scholar
• Di Maio M, Perrone F. Palonosetron: more than just another option? Lancet Oncol. 2009;10:100–101.
   PubMed Web of Science ®Google Scholar
• Howell J, Smeets J, Drenth HJ, et al. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract. 2009;15:223–231.
   PubMedGoogle Scholar
• Duggan ST, Curran MP. Transdermal granisetron. Drugs. 2009;69:2597–2605.
   PubMed Web of Science ®Google Scholar
• Tuca A. Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review. Cancer Manag Res. 2010;2:1–12.
   Google Scholar
• Keating GM, Duggan ST, Curran MP. Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy. CNS Drugs. 2012;26:787–790.
   PubMed Web of Science ®Google Scholar
• Ottoboni T, Gelder MS, O’Boyle E. BiochronomerTM technology and the development of APF530, a sustained release formulation and granisetron. J Exp Pharmacol. 2014;6:15–21.
   PubMedGoogle Scholar
• Kubota K, Saito M, Aogi K, et al. Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens. Support Care Cancer. 2016;24:4025–4033.
   PubMed Web of Science ®Google Scholar
• Blum RA, Majumdar A, McCrea J, et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther. 2003;25:1407–1419.
   PubMed Web of Science ®Google Scholar
• Gurpide A, Sadaba B, Martin-Algarra S, et al. Randomised crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-induced chemotherapy. Oncologist. 2007;12:1151–1155.
   PubMed Web of Science ®Google Scholar
• Ohzawa H, Miki A, Hozumi Y, et al. Comparison between the antiemetic effects of palonosetron and granisetron in breast cancer patients treated with anthracycline based regimens. Oncol Lett. 2015;9:119–124.
   PubMed Web of Science ®Google Scholar
• Fujiwara S, Terai Y, Tsunetoh S, et al. Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer. J Gynecol Oncol. 2015;26:311–319.
   PubMed Web of Science ®Google Scholar
• Kitayama H, Tsuji Y, Sugiyama J, et al. Efficacy of palonosetron and 1 day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study. Int J Clin Oncol. 2015;20:1051–1056.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Yamanaka T, Hashimoto H, et al. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol. 2016;27:1601–1606.
   PubMed Web of Science ®Google Scholar
• Shi Q, Li W, Li H, et al. Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison. Oncotarget. 2016;7:24402–24414.
   PubMed Web of Science ®Google Scholar
• Kimura H, Yamamoto N, Shirai T, et al. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study. Cancer Med. 2015;4:333–341.
   PubMed Web of Science ®Google Scholar
• Doggrell SA, Hancox JC. Cardiac safety concerns for ondansetron, and antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf. 2013;12:421–431.
   PubMed Web of Science ®Google Scholar
• Mason JW, Moon TE. Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management. Cancer Manag Res. 2013;5:179–185.
   PubMedGoogle Scholar
• Boccia RV, Gordan LN, Clark G, et al., Sancuso Study Group. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011;19:1609–1617.
   PubMed Web of Science ®Google Scholar
• Kim JE, Hong YS, Lee JL, et al. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. Support Care Cancer. 2015;23:1769–1777.
   PubMed Web of Science ®Google Scholar
• Seol YM, Kim HJ, Choi YL, et al. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study. Support Care Cancer. 2016;24:945–952.
   PubMed Web of Science ®Google Scholar
• Mason JW, Moon TE, O’Boyle E, et al. A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation. Cancer Manag Res. 2014;6:181–190.
   PubMed Web of Science ®Google Scholar
• Gabrail N, Yanagihara R, Spaczyński M, et al. Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials. Cancer Manage Res. 2015;7:83–92.
   PubMed Web of Science ®Google Scholar
• Raftopoulos H, Cooper W, O’Boyle E, et al. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Support Care Cancer. 2015;23:723–732.
   PubMed Web of Science ®Google Scholar
• Boccia R, Cooper W, O’Boyle E. Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy. J Community Support Oncol. 2015;13:38–46.
   PubMedGoogle Scholar
• Hesketh PJ, Kris MG, Grunberg SM. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103–109.
   PubMed Web of Science ®Google Scholar
• Basch E, Prestud AA, Hesketh PJ. Antiemetics: Americal Society of Clinical Oncology Practice Guideline update. J Clin Oncol. 2011;29:4189–4198.
   PubMed Web of Science ®Google Scholar
• Raftopoulos H, Boccia R, Cooper W, et al. Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria. Future Oncol. 2015;11:2541–2551.
   PubMed Web of Science ®Google Scholar
• Boccia R, O’Boyle E, Cooper W. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy. BMC Cancer. 2016;16:166. DOI:10.1186/s12885-016-2186-4
   PubMed Web of Science ®Google Scholar
• Schnadig ID, Agajanian R, Dakhill C, et al. APF530 (granisetron injection extended-release) in a three-drug regimen of CINV in highly emetogenic chemotherapy. Future Oncol. 2016;12:1469–1481.
   PubMed Web of Science ®Google Scholar
• Granisetron dosage. [cited 2017 Jun 7]. Available from: https://www.drugs.com/dosage/granisetron.html
   Google Scholar
• SUSTOL; Highlights of prescribing information. [cited 2017 Jun 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022445s000lbl.pdf
   Google Scholar